Human hepatocellular carcinoma is one of the most frequent malignant tumors. It may occur following exposure to various agents, including viruses and chemical carcinogens ; however, the underlying mechanisms of the hepatocarcinogenesis are not known. The present study is the result of our search for genes which may be abundantly expressed in human primary liver carcinoma. One of these genes was found to encode the human hepatocyte growth factor-like protein (HGFLP), also known as macrophage-stimulating protein. HGFLP is structurally homologous to hepatocyte growth factor, a potent growth factor for liver. HGFLP mRNA was also found to be overexpressed in a hepatoblastoma sample and in a sample of subacute fulminant hepatic necrosis. In a study on the effects of cytokines on the expression of HGFLP, we found that IL-6 increased expression of HGFLP mRNA in Hep G2 cells, but IL-1K, IL-1L and TNF-K had no effect. An increase in HGFLP could be the result of inflammation and/or tissue injury and its overexpression may prove to be useful as an indicator of hepatoma. ß
Introduction
Hepatocellular carcinoma (HCC) is a widespread disease, its annual incidence being estimated between 0.25 and 1 million new cases per year [1] . Etiological studies have shown that the occurrence of HCC is related to factors such as hepatitis B virus or hepatitis C virus infection, a£atoxin B1, and hepatic cirrhosis [2^6] . These factors can cause mutations in the structural and regulatory genes of hepatocytes, and result in the abnormal expression of cellular genes. It is believed that hepatocyte necrosis and the proliferation process (liver regeneration) resulting from chronic liver disease are also involved in the development of HCC. While growth factors such as epidermal growth factor, transforming growth factor-K, hepatocyte growth factor (HGF) and transforming growth factor-L, and protooncogene products, such as c-fos, c-myc, p53, and the ras gene family (c-Haras, c-Ki-ras, and N-ras) are regulators during liver regeneration [7^10], aberrant expression of these genes is of clinical signi¢cance in the development of HCC [11^14] . Cytokines, such as interleukin-6 (IL-6), which are involved in the acute phase response and liver regeneration [15, 16] , may also be involved. It is likely that a complex interplay of regenerative cell growth induced by hepatic in£ammatory disease, consequences of viral integration and chromosomal alterations, as well as genetic and environmental host factors, all participate in the development of the malignant phenotype.
The identi¢cation of markers for HCC with increased expression in advanced lesions would be extremely useful in the detection of tumors or in the evaluation of prognosis. However, there is still limited information available on genes associated with HCC. In the present work we used cDNA subtraction hybridization [17] to identify genes which are overexpressed in liver tumor tissue when compared to the corresponding normal tissue. As altered gene expression is a common feature of neoplastic cells, we found by this method genes which are more abundantly expressed in liver tumor cells when compared to normal cells. In this article, we report an increase in expression of hepatocyte growth factorlike protein (HGFLP), a protein with structural similarities to HGF [18] , in liver tumor cells. We also report the e¡ect of treatment by several cytokines on the expression of HGFLP mRNA in Hep G2 cells.
Materials and methods

Liver samples
The liver sample used as a source of mRNA for the tumor cDNA library was a primary hepatocellular carcinoma from a patient who was also positive for hepatitis B virus. Other liver samples used to examine the expression level of the isolated clones were obtained from a hepatocellular carcinoma patient with hepatitis and the non-tumorous liver tissue from the same patient, from a rectum carcinoma patient with tumor metastasized to the liver and the uninvolved liver part from the same patient, from a hepatoblastoma patient, from a malignant hemangioendothelioma patient, the uninvolved liver parts from two colon carcinoma patients with tumor metastasized to the liver. These samples were obtained through the Cooperative Human Tissue Network, University of Alabama at Birmingham. Two liver specimens with fulminant hepatic failure, one with chronic active hepatitis, and one with subacute fulminant hepatic necrosis were obtained from Dr. R.M. Galbraith, Medical University of South Carolina. Samples were obtained with the approval of, and in accordance with, guidelines established by the Medical University of South Carolina Institutional Review Board for Human Research.
Cell lines
Hepatoma cell lines Hep G2 and Hep 3B were obtained from American Type Culture Collection (Rockville, MD), and were cultured in Eagle's minimal essential medium (MEM) (Hazleton, Lenexa, KS) supplemented with 10% fetal calf serum (FCS) (Hyclone, Logan, UT) in 75-cm 2 £asks at 37³C in humidi¢ed atmosphere containing 5% CO 2 in air. The cells were allowed to grow to about 80% con£uence before extraction of the total RNA. THP1 monocytes (from Dr. J.M. Goust, Medical University of South Carolina) were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. Cultured human foreskin ¢broblasts were kindly provided by Dr. Maria Trojanowska, Medical University of South Carolina.
RNA preparation and tumor cDNA library construction
Total cellular RNA was isolated from tissues by the guanidinium thiocyanate procedure [19, 20] . RNAs from cell lines were extracted with a modi¢ed version of this procedure using an RNAsol B kit (Biotecx, Houston, TX) or an Ultraspect RNA kit (Biotecx) according to the manufacturer's protocol. Polyadenylated RNA was puri¢ed through two cycles of binding to and elution from an oligo-dT cellulose column [21] . First and second strand cDNA synthesis from liver tumor mRNA were performed essentially according to the procedure of Gubler and Ho¡man [22] , using a kit from Gibco BRL (Gaithersburg, MD). The cDNA was blunt-ended by Klenow fragment, and size-selected on a Sephacryl S-400 spin column (Pharmacia, Piscataway, NJ). An EcoRI/NotI adapter was ligated to each end of the cDNA by T4 DNA ligase (Stratagene, La Jolla, CA). The DNA was then ligated to pre-prepared V ZAP II arms, and the V ZAP II phage DNA was packaged with Gigapack II packaging extracts (Stratagene) according to the supplier's protocol.
Subcloning procedure for non-tumor cDNA
A non-tumoral human liver cDNA library in V gt 11 was purchased from Clontech (Palo Alto, CA). We subcloned the cDNA inserts from this library into V ZAP II vector. The cDNA inserts were PCR-ampli¢ed using forward and reverse primers (New England Biolabs, Beverly, MA) with sequences complementary to sites adjacent to the EcoRI site in the V gt 11 vector. EcoRI digestion was then performed to generate EcoRI sites at both ends of the inserts for the cloning, and the inserts were then puri¢ed on a Sephadex G-50 column. The cDNA inserts were then ligated into EcoRI-digested V ZAP II arms as described above, followed by packaging and infection of XL1-Blue cells.
Subtractive hybridization
cDNA library subtraction was performed by the protocol of Schweinfest et al. [17] . Biotinylation was according to Duguid et al. [23] and two rounds of streptavidin subtraction were performed according to Sive and St. John [24] .
DNA dot blot analysis
Poly(A)
RNAs prepared from both tumor liver and non-tumor liver tissues were used as templates for the synthesis of 32 P-labeled ¢rst strand cDNA [25] . Plasmid DNA from each clone in the subtractive library was prepared by a mini-prep procedure [26] . Five Wg of each DNA were applied onto a Nytran membrane (Schleicher and Schuell, Keene, NH) and cross-linked in a Stratalinker (1200 J/cm 2 ) (Stratagene). Duplicate dot blot membranes were allowed to hybridize with the radiolabeled cDNA probes from tumorous and non-tumorous liver.
DNA partial sequencing and computer analysis
The cDNA inserts were sequenced using a cycle sequencing protocol (Gibco BRL). Primers were designed according to sequences in pBluescript vector £anking the EcoRI site (Primer SK, CTCTAGAAC-TAGTGGATCCC; Primer KS, GGTATCGATAA-GCTTGATATC), and were labeled at the 5P-ends with T4 kinase according to the manufacturer's protocol (Gibco BRL). Sequences obtained were examined for similarity in the GenBank nucleic acid database through the`Basic Local Alignment Search Tool' (BLASTN) program for nucleotide comparison.
Cell culture and cytokine treatment
Hep G2 cells were cultured in MEM supplemented with penicillin (50 U/ml), streptomycin (50 Wg/ml) and 10% FCS. The cells were plated on 6-well plastic plates and incubated at 37³C in a humidi¢ed atmosphere of 5% CO 2 in air. To study the e¡ect of cytokines on the expression of clone 18 (HGFLP), 1U10 6 cells per well were incubated in MEM medium with 10% FCS and were allowed to grow until 95% con£uent. The cells were then preincubated with serumfree MEM for 4 h to remove residual serum [27] . Following preincubation, the cells were incubated with serum-free MEM alone or MEM containing the cytokine to be tested. The cytokines tested were recombinant human IL-1K and IL-1L (RpD, Minneapolis, MN), TNF-K (Gibco BRL, Gaithersburg, MD), and IL-6 (Genzyme, Cambridge, MA).
Northern blot hybridization
The cDNA inserts of selected subtractive clones were released from the pBluescript vector by either NotI or EcoRI digestion. The cDNA inserts were eluted from the agarose gel by centrifugation through silanized glass wool at 2500 rpm for 20 min [21] , and were labeled by the random primer labeling procedure with 32 P [28] , using the Prime-It II kit (Stratagene). The probes were then puri¢ed by ethanol precipitation. Ten or 20 Wg of total RNA from each sample were fractionated by electrophoresis on 1.2% agarose gels containing 6% formaldehyde [21] . After completion of electrophoresis, the gels were stained with ethidium bromide, illuminated with UV light and photographed to verify equal loading of rRNA bands. The denatured RNA was then transferred to Nytran membranes by capillary elution [21] . After overnight transfer, the membranes were photographed under UV light in order to verify equal transfer of ethidium bromide-stained ribosomal RNA bands. The RNA was then cross-linked to the membrane as described above. Hybridization and washing were performed as described [29] . The ¢lter was autoradiographed using tungstate intensi¢er screens at 370³C for various periods of time.
Results
Preliminary screening of the subtraction library-di¡erential DNA hybridization
A total of 87 tumor enriched subtracted recombinant cDNAs were obtained. Among these 87 clones, only some of them were expected to be speci¢c for liver tumor. As a ¢rst step in analyzing our clones, DNA di¡erential hybridization was used to identify tumor-speci¢c sequences on dot blots. We used the ¢rst strand cDNAs synthesized from the non-tumor and tumor liver RNAs as probes to hybridize to each clone, respectively. A number of the clones displayed increased hybridization signal intensity with the tumor cDNA probe in this preliminary screening, but none were found to hybridize only to the tumor probe (not shown). Partial sequence analysis was performed on selected recombinants from the subtractive library, and the sequence of each was compared to the Genbank nucleic acid database through the BLASTN program. Clone 18 was found to be HGFLP.
Complete sequencing of clone 18
The complete sequence of clone 18 is 908 bp in length, and has 97.6% identity with the published sequence for the HGFLP gene. When compared with the published cDNA sequences and the translated amino acid sequences of the cDNA coding for human HGFLP [18] , the clone 18 insert is located at the 3P-end of the HGFLP cDNA which encodes for the serine protease-like domain. This particular transcript still contained introns M and N, but not O, P or Q. In addition, this clone contained 47 nucleotides from the DNF15S1 locus [30] , suggesting that this transcript came from chromosome 1 and not from chromosome 3. These chromosome 1-speci¢c sequences begin 41 nucleotides 3P to the termination codon and represent the boundary of an ancient transposition and duplication of the HGFLP gene from chomosome 3 [30] .
Northern blot analysis of tumors and cell lines
The clone 18 cDNA insert was released by Not I digestion, puri¢ed by agarose gel electrophoresis, labeled with K-32 P dATP and used as a probe to hybridize to the total RNAs from tumor and non-tumor liver tissues (Fig. 1) . Clone 18, (HGFLP) clearly hybridized to a 2.4 kb mRNA species from tumor liver more strongly than for non-tumor liver. Clone 18 also hybridized to mRNA from Hep 3B cells and Hep G2 cells, but no bands were seen for foreskin ¢broblast RNA (Fig. 2A, lanes 1^3 ). An additional band of 3.0 kb mRNA was also seen for the Hep 3B and Hep G2 cells as well as for some of the other samples (see below). The tumor RNA yielded a stronger signal than the non-tumor RNA, thus suggesting that HGFLP was expressed at an increased level in HCC. In addition, our results showed that, unlike HGF [31] , the protein to which HGFLP is similar in structure, HGFLP is expressed by both Hep G2 and Hep 3B hepatoma cell lines. We then examined the expression of HGFLP mRNA in other liver tumor and non-invaded parts from the same liver, as well as in tissues from other liver diseases by means of Northern blot hybridization (Fig. 2B ). We found that the level of HGFLP expression was higher in another HCC sample (lane 1) than in the corresponding normal liver tissue from the same patient (lane 2). The expression level of HGFLP was found to be even higher in a hepatoblastoma sample (lane 6). In addition, the 3.0-kb mRNA species could be detected in this tumor sample. By contrast, HGFLP expression levels in nonhepatocyte derived tumors (liver metastasis of a rectal carcinoma, lane 3; hemangioendothelioma (a vascular tumor) from liver, lane 5) appeared to be lower than that for uninvolved liver tissues (lanes 2 and 4). This is in agreement with HGFLP in the liver being produced only by hepatocytes [32] . The faint bands seen in lanes 3 and 5 are likely to originate from the normal hepatocytes surrounding the metastasis. No mRNA expression was observed either in two nontumorous liver samples from patients with colon carcinoma (lanes 7 and 8) or in the THP1 monocytes (lane 13).
We also examined HGFLP mRNA expression in liver samples from chronic hepatic diseases and fulminant hepatic failure (lanes 9^12). We found that no HGFLP could be detected in the fulminant hepatic failure samples (lanes 10 and 11) . The metabolism of these hepatocytes may be drastically altered as a result of cell necrosis. As shown on lanes 9 and 12, corresponding to chronic active hepatitis and subacute hepatic necrosis samples, respectively, some HGFLP was produced by these livers.
E¡ect of IL-6 on HGFLP mRNA expression in Hep G2 cells
To determine the e¡ect of IL-6 on the expression of the HGFLP mRNA by Hep G2 cells, 70% con£uent Hep G2 cells were incubated with serum-free MEM medium alone, or with IL-6 at a concentration of 25 ng/ml. Total cellular RNAs were extracted at di¡erent time points of 12, 24, 36, 48, and 60 h. Ten Wg of total RNA were loaded and fractionated by agarose/formaldehyde gel electrophoresis. Equal loading of the gel was determined from ethidium bromide staining of the gel and the Nytran membrane after the Northern transfer. As shown in Fig.  3 , HGFLP mRNA expression was increased time dependently as compared to the L-actin control after IL-6 treatment in Hep G2 cells. The increase in HGFLP expression was already detectable after 12 h treatment of IL-6, and reached the highest level at 24 h. The expression level was still higher at 60 h than for the untreated samples. The maximum extent of the increase in mRNA expression at 24 h after the treatment was estimated to be about two to three fold. The increase in HGFLP mRNA expression by IL-6 was also dose-dependent as compared to the L-actin control. As Fig. 4 shows, we treated the Hep G2 cell with IL-6 at the concentration of 2.5, 5.0, 10.0, 25.0, 50.0 and 100.0 ng/ml, respectively, and extracted the RNA after a 48-h incubation. HGFLP mRNA was elevated with 2.5 ng/ml IL-6, reached the maximum at an IL-6 concentration of 25 ng/ml, and stayed at the same level even in the presence of 100 ng/ml of IL-6. The above indicates that IL-6 stimulates the transcription of HGFLP in a time-and dose-dependent manner. Similar time (up to 48 h) and dose-dependent (2.5^100 ng) experiments were performed for IL-1K, IL-1L and TNF-K. In contrast to the results for IL-6, IL-1K, IL-1L And TNF-K had no signi¢cant e¡ect on the expression of HGFLP mRNA in Hep G2 cells (data not shown).
In summary, the above results suggest that HGFLP mRNA can only be detected in hepatocytes in our experiments and not in other cell types, such as monocytes, or rectal cancer cells. The mRNA of HGFLP is decreased in the fulminant hepatic failure sample, as also reported by others [33] , and appears to be increased in the subacute hepatic necrosis sample. The above results also suggest that HGFLP is overexpressed in human hepatocellular carcinoma as well as in hepatoblastoma. Finally, IL-6, but not the other cytokines tested, increases the expression of HGFLP mRNA in Hep G2 cells.
Discussion
Subtraction hybridization as a means for cloning a speci¢c subset of mRNA sequences has been applied successfully to a wide range of biological problems and has proven to be very e¤cient in isolating sequences expressed di¡erentially between two di¡erent tissues [17,23,34^38] . Using subtraction hybridization, we identi¢ed sequences that are expressed at increased levels in HCC, one of which was HGFLP.
HGFLP was ¢rst described by Han et al. [18] and was named hepatocyte growth factor-like protein because its structural organization is similar to HGF, a growth factor with broad target speci¢city [39] . The two proteins each contain four kringle domains followed by a serine protease-like domain and have 50% homology in amino acid sequence. More recently, HGFLP was reported to be identical to a macrophage-stimulating protein (MSP) [40, 41] . MSP is the name originally given to a human serum protein that makes resident peritoneal mouse macrophages capable of responding to the chemoattractant C5a [42] .
A striking feature of the sequence of clone 18 is that this cDNA clone still retains some introns and contains sequences from the DNF15S1 locus in chromosome 1. This is a situation that was also observed by Yoshimura et al. [41] for some of their MSP cDNA clones. The human HGFLP/MSP genes express two mRNAs species of 2.4 and 3.0 kb [18] , and the clone 18 probe revealed the same expression pattern, again indicating the likelihood for retained introns or other alternatively spliced species [41] . The junction sequence we see in the 3P-untranslated region of our clone is thought to be due to an ancient transposition of chromosome 3 sequences containing the HGFLP/MSP gene to chromosome 1 [30] with the sequences upstream of the junction remaining virtually identical [41] in the duplicated genes. Per- haps the di¡ering 3P-sequences for the chromosome 1 genes cause the pre-mRNA to be less e¤ciently processed, resulting in a buildup of mRNA species that still retain some of their introns. The relative contributions to functional HGFLP from these genes is not known. It remains to be determined whether mRNA from chomosome 1 is more often misprocessed and perhaps represents the bulk of the 3.0 kb RNA.
The mRNA for the HGF has been identi¢ed in rats in several tissues, including brain, lung, heart, thymus, liver, spleen, and kidney tissue [43] . In the liver, HGF mRNA is present in non-parenchymal fat-storing cells [44] , and its expression increases following partial hepatectomy in rats [45, 46] . In contrast to the widespread expression pattern of HGF, HGFLP was reported to be expressed primarily in the liver in embryonic and adult mice and rats [18, 47] , where it is synthesized by hepatocytes [32] . In our experiments, expression of HGFLP was found in liver (both normal and tumor) and in hepatoma cell lines (Hep G2 and Hep 3B), but not in foreskin ¢broblast or monocytes. This is in agreement with the results of others that HGFLP expression is primarily in the liver [47] .
The similarity in protein structure between HGFLP and HGF suggests that they might function in cell growth regulation in a similar manner. However, their ultimate biological role is likely to be different since they are produced by di¡erent cell types. A possible function of HGFLP/MSP might be its involvement in protective responses during the in£ammatory reactions caused by infections, tissue injury [40] , and malignancy through activation of macrophages. Bezzera et al. [48] have found that HGFLP mRNA is increased during liver regeneration and in£ammation as well as in turpentine-induced acute phase response in rats. In this regard, we have found that IL-6, a major acute phase response regulatory cytokine, causes an increase in HGFLP mRNA in Hep G2 cells. However, Wang et al. [49] have shown that serum MSP is not increased in lipopolysaccharide-challenged human subjects, leaving the acute phase reactant nature of HGFLP/MSP open for further study. These authors [49, 50] suggest a model in which the protein circulates as pro-MSP and, upon conversion to MSP [51] , would cause transient activation of tissue macrophages, presumably by binding to the RON tyrosine kinase receptor [52^55]. In fact, putative IL-6 response elements [56] were found in the RON gene promoter [57] and can also be seen at positions (3525) and (3715) in the HGFLP promoter [58] ; the latter giving validity to our ¢nding of IL-6 induction of HGFLP mRNA.
In our results for treatment of Hep G2 cells, while HGFLP mRNA expression was increased by IL-6, IL-1K, IL-1L and TNF-K had no e¡ect. This is the exact opposite of what Tamura et al. [59] found for HGF expression in human ¢broblasts where IL-1K, IL-1L, and TNF-K all increased expression whereas IL-6 had no e¡ect. IL-6, IL-1K, IL-1L and TNF-K are all involved in the acute phase response reaction and liver repair and regeneration process, and IL-6 is the major mediator of these responses. Thus the two proteins, HGFLP and HGF, may both act as growth factors, but act on di¡erent cellular targets and are regulated di¡erently as well.
HGFLP/MSP activates macrophages and thus can play a role in the body's self-defense. In turn, macrophages can produce and secrete cytokines, including IL-6, and can trigger the function of the defense system. Here we can see a positive feedback loop, in which hepatocytes produce and secrete HGFLP/ MSP, and these proteins activate the macrophage (and thus, speculatively, Kup¡er cells in liver) to produce cytokines such as IL-1 and IL-6. IL-6 will then further stimulate the production of HGFLP/ MSP. That MSP can speci¢cally induce IL-6 in cells bearing the RON receptor has been shown for example in megakaryocytes [60] .
In experimental models, IL-6 has been found to stimulate the growth of human colorectal carcinoma cell lines [61] and renal cell cancer [62] , but inhibit the growth of human breast cancer cell lines [63] and human lung cancer cell lines [64] . Therefore, the role of IL-6 in tumor biology appears to be di¡erent for di¡erent kinds of tumors and is unknown for hepatocellular carcinoma. In our experiments, HGFLP was overexpressed in hepatocellular carcinoma. The basis for the increased expression of HGFLP is not readily apparent. Could this be the result of an in£ammatory reaction in which IL-6 expression was increased, and in turn, IL-6 stimulated the expression of HGFLP? Alternatively, HGFLP overexpression could be the result of the malignancy, and the overexpressed HGFLP is responsible for the continued development of the liver tumor via the macrophage feedback loop. In either case, IL-6 might then be a stimulator of liver cancer. Further study of the relationship between HGFLP and IL-6 and the roles they play in liver malfunction may well reveal at least part of the mechanism for hepatocarcinogenesis.
